# Open-Label Study Of Exemestane With Or Without Celecoxib In Postmenopausal Women With ABC Having Progressed On Tamoxifen

> **NCT00038103** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 111 (actual)

## Conditions studied

- Breast Neoplasms

## Interventions

- **DRUG:** Exemestane
- **DRUG:** Celecoxib + Exemestane

## Key facts

- **NCT ID:** NCT00038103
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-01
- **Primary completion:** 2008-03
- **Final completion:** 2008-03
- **Target enrollment:** 111 (ACTUAL)
- **Last updated:** 2010-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00038103

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00038103, "Open-Label Study Of Exemestane With Or Without Celecoxib In Postmenopausal Women With ABC Having Progressed On Tamoxifen". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT00038103. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*